Supernus Pharmaceuticals SUPN Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's income tax?
- Supernus Pharmaceuticals (SUPN) reported income tax of -$3.66M in Q1 2026.
- How has Supernus Pharmaceuticals's income tax changed year-over-year?
- Supernus Pharmaceuticals's income tax decreased by 161.0% year-over-year, from $6M to -$3.66M.
- What is the long-term trend for Supernus Pharmaceuticals's income tax?
- Over 2 years (2021 to 2024), Supernus Pharmaceuticals's income tax has grown at a 9.2% compound annual growth rate (CAGR), from $20.14M to $24.01M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.